Microdosing of a carbon-14 labeled protein in healthy volunteers accurately predicts its pharmacokinetics at therapeutic dosages

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 2, 2015, Pages 196-204

  Vlaming, M L H ^a   Van Duijn, E ^a   Dillingh, M R ^b   Brands, R ^c   Windhorst, A D ^d   Hendrikse, N H ^d   Bosgra, S ^a   Burggraaf, J ^b   De Koning, M C ^a   Fidder, A ^a   Mocking, J A J ^a   Sandman, H ^a   De Ligt, R A F ^a   Fabriek, B O ^a   Pasman, W J ^a   Seinen, W ^c,e   Alves, T ^f   Carrondo, M ^f   Peixoto, C ^f   Peeters, P A M ^b   Vaes, W H J ^a   more..

^a TNO   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c AMRIF BV   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f GenIBET IBET   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CARBON 14; HUMAN RECOMBINANT PLACENTAL ALKALINE PHOSPHATASE C 14; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE, PLACENTAL; CARBON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ISOENZYME; RECOMBINANT PROTEIN;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MICRODOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; HEADACHE; HUMAN; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE CALCULATION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; NETHERLANDS; PROCEDURES; STATISTICAL MODEL; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; AREA UNDER CURVE; CARBON RADIOISOTOPES; DOUBLE-BLIND METHOD; DRUG DOSAGE CALCULATIONS; GPI-LINKED PROTEINS; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; ISOENZYMES; LINEAR MODELS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NETHERLANDS; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84943356495     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.131     Document Type: Article

References (33)

1. EvaluatePharma. Surveying tomorrow?s BioPharma landscape: the NASDAQ biotech index up close 2012
2. Bugelski, P.J. & Treacy, G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6, 10-16 (2004).
3. Wierda, D., Smith, H.W. & Zwickl, C.M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158, 71-74 (2001).
4. Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature 477, 526-528 (2011).
5. Bae, S.K. & Shon, J.H. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials. Arch. Pharm. Res. 34, 1789-1798 (2011).
6. Garner, R.C. & Lappin, G. The phase 0 microdosing concept. Br. J. Clin. Pharmacol. 61, 367-370 (2006).
7. Lappin, G., et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80, 203-215 (2006).
8. Henderson, P.T. & Pan, C.X. Human microdosing for the prediction of patient response. Bioanalysis 2, 373-376 (2010).
9. Johnson, G. Using microdosing to enhance development. Genetic Engineering and Biotechnology News (2008).
10. European Medicines Agency. Position paper on non-clinical safety studies to support clinical trials with a single microdose. (2004).
11. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry, investigators, and reviewers. (2006).
12. European Medicines Agency. Committee for Medical Products for Human Use. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigation medicinal products. EMEA/CHMP/SWP/28367/07 (2007).
13. Committee for Medical Products for Human Use. Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. (2008).
14. Salehpour, M., Possnert, G. & Bryhni, H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal. Chem. 80, 3515-3521 (2008).
15. Vogel, J.S., Grant, P.G., Buchholz, B.A., Dingley, K. & Turteltaub, K.W. Attomole quantitation of protein separations with accelerator mass spectrometry. Electrophoresis 22, 2037-2045 (2001).
16. Van Duijn, E., Sandman, H., Grossouw, D., Mocking, J.A., Coulier, L. & Vaes, W.H. Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range. Anal. Chem. 86, 7635-7641 (2014).
17. Muller, P.Y. & Brennan, F.R. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 85, 247-258 (2009).
18. Rezende, A.A., Pizauro, J.M., Ciancaglini, P. & Leone, F.A. Phosphodiesterase activity is a novel property of alkaline phosphatase from osseous plate. Biochem. J. 301 (Pt 2), 517-522 (1994).
19. Poelstra, K., Bakker, W.W., Klok, P.A., Hardonk, M.J. & Meijer, D.K. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab. Invest. 76, 319-327 (1997).
20. Kats, S., et al. Prophylactic treatment with alkaline phosphatase in cardiac surgery induces endogenous alkaline phosphatase release. Int. J. Artif. Organs 35, 144-151 (2012).
21. Kats, S., et al. Anti-inflammatory effects of alkaline phosphatase in coronary artery bypass surgery with cardiopulmonary bypass. Recent Pat. Inflamm. Allergy Drug Discov. 3, 214-220 (2009).
22. Beumer, C., Wulferink. M., Raaben, W., Fiechter, D., Brands, R. & Seinen, W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J. Pharmacol. Exp. Ther. 307, 737-744 (2003).
23. European Microdosing AMS Partnership Programme (EUMAPP). Outcomes from EUMAPP - A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. (2012).
24. Lappin, G., et al. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci. 43, 141-150 (2011).
25. Salehpour, M., Ekblom, J., Sabetsky, V., Håkansson, K. & Possnert, G. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals. Rapid Commun. Mass Spectrom. 24, 1481-1489 (2010).
26. Lamers, R.J., De Jong, A.F., L-opez-Guti-errez, J.M. & G-omez-Guzm-An, J. Iodine-129 microdosing for protein and peptide drug development: erythropoietin as a case study. Bioanalysis 5, 53-63 (2013).
27. Sugiyama, Y. & Yamashita, S. Impact of microdosing clinical study - why necessary and how useful?. Adv. Drug Deliv. Rev. 63, 494-502 (2011).
28. Klein, M., Vaes, W.H.J., Fabriek, B., Sandman, H., Mous, D.J.W. & Gottdang, A. The 1 MV multi-element AMS system for biomedical applications at the Netherlands Organization for Applied Scientific Research (TNO). Nucl. Instrum. Methods Phys. Res. B. 294, 14-17 (2013).
29. Keck, B.D., Ognibene, T. & Vogel, J.S. Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2, 469-485 (2010).
30. Higton, D., Young, G., Timmerman, P., Abbott, R., Knutsson, M. & Svensson, L.D. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry. Bioanalysis 4, 2669-2679 (2012).
31. Stuiver, M. International agreements and the use of the new oxalic acid standard. (1983).
32. Xu, X., Khosh, M.S., Druffel E.R.M., Trumbore, S.E. & Southon, J.R. Is the consensus value of anu sucrose (IAEA C-6) too high?. Radiocarbon 52, 866-874 (2010).
33. Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D. & the R Development Core Team. NLME: Linear and nonlinear mixed effects models. R Foundation for Statistical Computing version 3.1-100 (2011).